John M. Vierling

Boceprevir for Previously Treated Chronic HCV Genotype 1 Infection

Bruce R. Bacon, Stuart C. Gordon, Eric Lawitz et al. · New England Journal of Medicine · 2011 · 1.6K citations · Full text

Pharmacy, Infectious Diseases, Pharmacotherapy +17

Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial

Zobair M. Younossi, Vlad Ratziu, Rohit Loomba et al. · The Lancet · 2019 · 1.2K citations · Full text

Medicine, Internal Medicine, Pharmacology +8

Elafibranor, an Agonist of the Peroxisome Proliferator−Activated Receptor−α and −δ, Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening

Vlad Ratziu, Stephen A. Harrison, Sven Francque et al. · Gastroenterology · 2016 · 1K citations · Full text

Medicine, Pharmacology, Pharmacotherapy +12

Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial

Paul Y. Kwo, Eric Lawitz, Jonathan McCone et al. · The Lancet · 2010 · 704 citations · Full text

Pharmacy, Infectious Diseases, Pharmacotherapy +17

Risk Factors and Comorbidities in Primary Biliary Cirrhosis: A Controlled Interview-Based Study of 1032 Patients *

Eric M. Gershwin, Carlo Selmi, Howard J. Worman et al. · Hepatology · 2005 · 631 citations · Full text

Medicine, Internal Medicine, Autoimmunity +15